The experimental Ebola vaccines from GlaxoSmithKline (NYSE:GSK) and NewLink Genetics (NASDAQ:NLNK) (NYSE:MRK) appear to be safe, based on interim results in a mid-stage trial
in Liberia. The vaccines, administered as a single injection, are being
evaluated for safety and efficacy on more than 600 people there. Based
on the positive results, the study will now progress to the next phase
of efficacy testing where additional volunteers will be injected with
one of the vaccines or placebo to see if their immune systems produce
anti-Ebola antibodies.
The Ebola epidemic, its course winding down, has claimed more than 10,000 lives.
0 Comments
Good day precious one, We love you more than anything.